Results 91 to 100 of about 2,921 (250)
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley +1 more source
ABSTRACT Ashwagandha, an adaptogen, is an important herb of Ayurveda used as a Rasayana for its various health benefits. This prospective, multi‐center, observational clinical study evaluates the safety (clinical and laboratory) of a standardized Ashwagandha Root Extract (ARE) on long‐term administration over 12 months. Male and female adults (N = 191)
Jaising Salve +6 more
wiley +1 more source
Subclinical hypothyroidism is characterized by elevated thyroid-stimulating hormone (TSH) levels with normal serum free thyroxine (fT4) and free triiodothyronine (fT3) concentrations.
Mustafa Mohammed Albassam +2 more
doaj +1 more source
Evaluation of Potential Hormonal Activities of Ashwagandha (Withania somnifera)
ABSTRACT Ashwagandha is a widely used herb in traditional medicine systems, particularly Ayurveda. Despite its extensive tradition, growing concerns regarding its potential endocrinological effects have prompted scientific scrutiny. This review systematically evaluates the current preclinical, clinical, and case study evidence concerning AS's effects ...
Günter Vollmer, Thomas Brendler
wiley +1 more source
Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha (Withania somnifera)
Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan +2 more
wiley +1 more source
Early postoperative levothyroxine initiation after total thyroidectomy for Graves’ disease
No evidence-based standards exist regarding levothyroxine (LT4) replacement therapy initiation timing in patients with hyperthyroid Graves’ disease undergoing total thyroidectomy.
Yuji Nagayama +11 more
doaj +1 more source
Abstract Background Autoimmune thyroiditis (AIT) may occur more frequently in dogs with hypoadrenocorticism (HA) than previously recognised. The objective of this study was to determine the presence of thyroglobulin autoantibodies (TgAAs) in dogs with HA.
Christin Emming +6 more
wiley +1 more source
Severe Hypothyroidism Causing Pre-Eclampsia-Like Syndrome
Objective. Analyzing and managing pre-eclampsia-like syndrome due to severe hypothyroidism. Methods. Presentation of a case of severe hypothyroidism due to Hashimoto’s syndrome, associated with a severe early-onset preeclampsia-like syndrome, managed in ...
Annalisa Inversetti +5 more
doaj +1 more source
European roe deer fecal samples were assayed to investigate the potential fluctuations of fecal thyroid hormone metabolites (FTMs) in response to environmental (e.g., the temperature, local densities) and individual (e.g., sex, age, body, and nutritional conditions) variables.
Valeria Pasciu +6 more
wiley +1 more source
Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act [PDF]
With substantial fixed costs of drug development, more common conditions can support more products. If additional pharmaceutical products are beneficial, they will attract greater consumption and promote better health, e.g. greater longevity.
Frank R. Lichtenberg, Joel Waldfogel
core

